Upgrade to SI Premium - Free Trial

Benchmark Reiterates Buy Rating on Abbott Labs (ABT), Following In-Line Q3 Results

October 16, 2025 8:31 AM
Benchmark reiterated a Buy rating and $145.00 price target on Abbott Labs (NYSE: ABT).The analyst commented, "Abbott Labs reported in-line ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles